Detalles de la búsqueda
1.
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial.
Cancer Immunol Immunother
; 72(3): 697-705, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36045304
2.
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis.
J Immunother Cancer
; 11(8)2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37536936
3.
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial.
Elife
; 112022 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35787784
4.
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
J Immunother Cancer
; 9(6)2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34117113
5.
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
J Immunother Cancer
; 9(10)2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34599031
6.
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.
J Immunother Cancer
; 4: 44, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27532019
Resultados
1 -
6
de 6
1
Próxima >
>>